A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of low tumor burden, CD20-positive follicular lymphoma
Ann Arbor Stage II, III, or IV
You may not be if
Not a candidate for treatment with rituximab as a single-agent
Evidence of transformation to a high grade or diffuse large B-cell lymphoma
Any previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroids
Any prior treatment with rituximab
Active, uncontrolled infection
Clareo Health | A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
